Literature DB >> 2786210

Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.

J H Nunberg1, M V Doyle, S M York, C J York.   

Abstract

Interleukin 2 (IL-2) occupies a central position in the cascade of events involved in the immune response. We were interested in determining whether IL-2 could function as an adjuvant to vaccination, to increase the immune response to vaccine immunogens. Using the National Institutes of Health test for rabies vaccine potency, we found that daily systemic administration of IL-2 in conjunction with inactivated rabies virus can increase the potency of vaccination in outbred mice at least 25-fold, as measured by survival following challenge with virulent rabies virus. Enhanced protection is not correlated with an increase in virus-neutralizing antibody titers, and we suggest that IL-2 acts to increase the cellular immune response to vaccination.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786210      PMCID: PMC287426          DOI: 10.1073/pnas.86.11.4240

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Propagation of Rabies Virus in Pig Kidney Cell Culture.

Authors:  M K Abelseth
Journal:  Can Vet J       Date:  1964-04       Impact factor: 1.008

2.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.

Authors:  B Dietzschold; H H Wang; C E Rupprecht; E Celis; M Tollis; H Ertl; E Heber-Katz; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody.

Authors:  B Dietzschold; M Tollis; C E Rupprecht; E Celis; H Koprowski
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

4.  A rapid reproducible test for determining rabies neutralizing antibody.

Authors:  J S Smith; P A Yager; G M Baer
Journal:  Bull World Health Organ       Date:  1973-05       Impact factor: 9.408

5.  Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon.

Authors:  T Basham; W Smith; L Lanier; V Morhenn; T Merigan
Journal:  Hum Immunol       Date:  1984-06       Impact factor: 2.850

6.  Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

Authors:  A Wang; S D Lu; D F Mark
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

7.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

8.  Response of bovine and porcine peripheral blood mononuclear cells to human recombinant interleukin 2(125).

Authors:  S Fong; M V Doyle
Journal:  Vet Immunol Immunopathol       Date:  1986-01       Impact factor: 2.046

Review 9.  NIH conference. Immunomodulators in clinical medicine.

Authors:  A S Fauci; S A Rosenberg; S A Sherwin; C A Dinarello; D L Longo; H C Lane
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

10.  Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.

Authors:  H Kawamura; S A Rosenberg; J A Berzofsky
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  13 in total

1.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

3.  Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis.

Authors:  D N Wedlock; B Vesosky; M A Skinner; G W de Lisle; I M Orme; B M Buddle
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects.

Authors:  H X Lin; C Gontier; M F Saron; P Perrin
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 5.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

6.  Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2.

Authors:  H P Hughes; M Campos; D L Godson; S Van Drunen Littel-Van den Hurk; L McDougall; N Rapin; T Zamb; L A Babiuk
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

7.  Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

Authors:  Y H Chow; W L Huang; W K Chi; Y D Chu; M H Tao
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Molecular chimerization of Pasteurella haemolytica leukotoxin to interleukin-2: effects on cytokine and antigen function.

Authors:  H P Hughes; M Campos; A A Potter; L A Babiuk
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

9.  General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines.

Authors:  Hans J Kueng; Victoria M Leb; Daniela Haiderer; Graça Raposo; Clotilde Thery; Sophia V Derdak; Klaus G Schmetterer; Alina Neunkirchner; Christian Sillaber; Brian Seed; Winfried F Pickl
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

Review 10.  Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.

Authors:  Ban Qi Tay; Quentin Wright; Rahul Ladwa; Christopher Perry; Graham Leggatt; Fiona Simpson; James W Wells; Benedict J Panizza; Ian H Frazer; Jazmina L G Cruz
Journal:  Vaccines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.